Mn Services Vermogensbeheer B.V. Purchases 2,700 Shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Mn Services Vermogensbeheer B.V. raised its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 1.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 159,800 shares of the company’s stock after acquiring an additional 2,700 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in GE HealthCare Technologies were worth $12,493,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. LGT Financial Advisors LLC boosted its position in GE HealthCare Technologies by 1,673.3% during the 3rd quarter. LGT Financial Advisors LLC now owns 266 shares of the company’s stock valued at $25,000 after acquiring an additional 251 shares in the last quarter. Capital Performance Advisors LLP bought a new stake in GE HealthCare Technologies during the 3rd quarter valued at approximately $26,000. Ashton Thomas Securities LLC bought a new stake in GE HealthCare Technologies during the 3rd quarter valued at approximately $26,000. Darwin Wealth Management LLC bought a new stake in GE HealthCare Technologies during the 3rd quarter valued at approximately $31,000. Finally, Continuum Advisory LLC lifted its holdings in shares of GE HealthCare Technologies by 101.8% during the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock valued at $31,000 after purchasing an additional 168 shares during the last quarter. 82.06% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on GEHC shares. Citigroup lifted their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Wells Fargo & Company lifted their target price on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Finally, Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and lifted their target price for the company from $95.00 to $103.00 in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $97.67.

GE HealthCare Technologies Price Performance

Shares of NASDAQ GEHC opened at $87.35 on Friday. GE HealthCare Technologies Inc. has a twelve month low of $74.51 and a twelve month high of $94.80. The firm has a market cap of $39.94 billion, a P/E ratio of 20.17, a PEG ratio of 3.19 and a beta of 1.15. The company has a 50 day moving average of $86.17 and a 200 day moving average of $86.10. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88.

GE HealthCare Technologies (NASDAQ:GEHC) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. The company had revenue of $5.32 billion during the quarter, compared to analyst estimates of $5.33 billion. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. As a group, research analysts expect that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.